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Background. Gliomas exhibit high glycolytic rates, and monocarboxylate transporters (MCTs) play a major role in the maintenance of the glycolytic metabolism 20 through the proton-linked transmembrane transportation of lactate. However, their role in gliomas is poorly studied. Thus, we aimed to characterize the expression of MCT1, MCT4, and their chaperone CD147 and to assess the therapeutic impact of MCT inhibition in 25 gliomas.
Methods. MCTs and CD147 expressions were characterized by immunohistochemistry in nonneoplastic brain and glioma samples. The effect of CHC (MCT inhibitor) and MCT1 silencing was assessed in in vitro and 30 in vivo glioblastoma models.
Results. MCT1, MCT4, and CD147 were overexpressed in the plasma membrane of glioblastomas, compared with diffuse astrocytomas and nonneoplastic brain. CHC decreased glycolytic metabolism, migration, and 35 invasion and induced cell death in U251 cells (more glycolytic) but only affected proliferation in SW1088
(more oxidative). The effectiveness of CHC in glioma cells appears to be dependent on MCT membrane expression. MCT1 downregulation showed similar effects 40 on different glioma cells, supporting CHC as an MCT1 inhibitor. There was a synergistic effect when combining CHC with temozolomide treatment in U251 cells. In the CAM in vivo model, CHC decreased the size of tumors and the number of blood vessels 45 formed.
Conclusions. This is the most comprehensive study reporting the expression of MCTs and CD147 in gliomas. The MCT1 inhibitor CHC exhibited antitumoral and anti-angiogenic activity in gliomas and, of 50 importance, enhanced the effect of temozolomide. Thus, our results suggest that development of therapeutic approaches targeting MCT1 may be a promising strategy in glioblastoma treatment. Tumor cells present uncontrolled cell proliferation, and during cancer progression, there are selective 70 active processes, namely adjustments of energy metabolism, to fuel cell growth and division. 3, 4 A classical phenomenon that describes this metabolic adaptation is a shift from oxidative phosphorylation to aerobic glycolysis, as a main source of ATP, even in the presence 75 of oxygen, known as the Warburg effect. 5 -7 The high rates of glycolytic metabolism produce high levels of lactate/H + (lactic acid), and to maintain the enhanced glycolytic flux and intracellular physiological pH, tumor cells perform the efflux of lactic acid into the ex-80 tracellular microenvironment, preventing intracellular acidosis and consequent cell death. 8 Therefore, tumor cells upregulate pH regulators, such as monocarboxylate transporters (MCTs), among others.
9
The MCT family comprises 14 members with similar 85 topology; however, only 4 isoforms (MCT1 -MCT4) are proton-linked monocarboxylate transporters, performing the transmembrane transportation of monocarboxylates, such as lactate, coupled with a proton, in an equimolar manner. 10, 11 Monocarboxylate transporters 90 play an important role in mammalian metabolism by regulating distinct pathways. 12, 13 In adult brain, MCT1 is expressed in endothelial cells of microvessels and in astrocytes. MCT2 is expressed in neurons, and MCT4 is present exclusively in astrocytes. 14, 15 The diffe-95 rence in MCT isoforms between astrocytes and neurons is explained by the lactate shuttle hypothesis, being lactate produced by astrocytes and used by neurons. 16, 17 MCT plasma membrane localization and activity is regulated by coexpression with chaperone 100 proteins, 11, 13 namely CD147 (basigin) for MCT1, MCT3, and MCT4 and gp-70 (embigin) for MCT2. 18, 19 Lactate produced by glycolytic tumor cells has an important role in the tumor microenvironment, being associated to poor prognosis. 20 Given the different affinity of 105 the MCT isoforms to lactate, 11 MCT1 and MCT4 are associated with lactate efflux and, therefore, have an important contribution to the maintenance of glycolytic metabolism and consequently tumor cell survival. Several studies described MCT expression in different 110 solid tumors, such as breast, 21 colorectal, 22 cervical, 23 lung, 24 and gastric 25 . However, expression of MCTs in gliomas and, in particular, in glioblastomas is not well characterized, and their role is poorly elucidated. There are only few studies in brain tumors that describe 115 the importance of MCTs in pH homeostasis and tumor growth. 26 -30 Because of the crucial importance of glycolytic metabolism to tumor cells and the pivotal role of MCTs in its maintenance, clarifying the role of MCTs in 120 glioma cell survival, proliferation, and aggressiveness is essential. Thus, our study aimed to explore MCTs as a new therapeutic target in glioblastomas. For that, assessment of MCT1 and MCT4 expressions, as well as CD147, in a series of human gliomas and evaluation 125 of the clinical-pathological significance of their expression profile was performed. Furthermore, the effect of MCT1 inhibition on the viability, proliferation, survival, and aggressiveness of glioma cells was evaluated in both in vitro and in vivo models. Biotechnology).
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Materials and Methods
Tissues Samples
Cell Viability and Proliferation Assays
Cells were plated into 96-well plates, at a density of 3 × 10 3 cells per well. The effect of treatment with CHC (0.6 -12 mM) on cell number (total biomass) was deter-265 mined at 24, 48, and 72 h by the sulforhodamine B assay (SRB, TOX-6; Sigma-Aldrich), according to the manufacturer's recommendations. IC 50 values (i.e., CHC concentration that corresponds to 50% of cell growth inhibition) were estimated from 3 independent experi-270 ments, each one in triplicate, using GraphPad Software. Cell proliferation assay was performed as previously described 32 and assessed under the treatment conditions previously described, for 5 mM and 10 mM of CHC. After CHC treatment, cells were incubated 275 with BrdU and its incorporation was assessed at 450 nm (l ref ¼ 655 nm), according to the manufacturer's protocol (BrdU, Cell Proliferation ELISA; Roche Diagnostics). Cell growth (total biomass) and cell proliferation for glioma siMCT1 cells and the effect of CHC 280 (1.25-15 mM) on cell number were performed as described above.
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A density of 3 × 10 3 U251 cells/well were seeded into 96-well plates. Treatments with TMZ (0.01 -1 mM), 285 CHC (0.6 -12 mM), and TMZ + CHC (0.05 -0.5 mM TMZ + 5 mM CHC) were done for 72 h. The effect of TMZ and CHC alone or in combination on cell growth was evaluated using the SRB assay, as described above. Combined effect of drugs was determined using 290 the CalcuSyn Software (Biosoft). Synergy or antagonism weas quantified by the combination index (CI), where CI ¼ 1 indicates an additive effect, CI , 1 indicates synergy, and CI . 1 indicates antagonis Q2 m. 33 Metabolism Assay (Extracellular Glucose and Lactate 295 Measurements)
Cells were plated in 48-well plates at a density of 4 × 10 4 cells per well and allowed to adhere overnight. Then, cells were treated with 5 mM and 10 mM CHC, and the cell culture medium was collected after 8, 12, 300 and 24 h for glucose and lactate quantification. For these time points, the total protein (expressed as total biomass) was assessed using the SRB assay. Cellular metabolism for glioma siMCT1 cells was assessed for 12 and 24 h. Glucose and lactate were quantified using 305 commercial kits (Roche and Spinreact, respectively), according to the manufacturer's protocols. Results are expressed as total mg/total biomass.
Apoptosis Assay
Apoptotic and necrotic cell populations were deter-310 mined by Annexin V-FLOUS Apoptosis Kit (Roche Diagnostics) according to the manufacturer's instructions. For that, 2.5 × 10 5 cells/well were seeded into 6-well plates in DMEM culture medium. Cells were treated with the IC 50 value of CHC for 72 h. After 315 that, cells were collected and Annexin V/PI staining was performed according to the manufacturer's instructions and incubated for 15 min at room temperature. The percentage of cell death was assessed by flow cytometry (LSRII model, BD Biosciences), a total of 50 000 320 events, and the results were analyzed using the FlowJo software (version 7.6; Tree Star).
Wound-Healing Assay
Cells were seeded in 6-well plates and cultured to at least 95% of confluence, and wound-healing assay was per-325 formed as described previously. 32, 34 Cells were treated with 5 and 10 mM CHC for 24 h, and the wound areas were photographed at 0 and 24 h. The relative migration distances were analyzed using Image J Software (version 1.41; National Institutes of Health). The rela-330 tive migration for siMCT1 glioma cells was assessed as described above. sion normalized for the control condition.
Chicken Chorioallantoic Membrane (CAM) Assay
Chicken chorioallantoic membrane assay was performed as previously described. 32, 34 In brief, fertilized chicken eggs (Pinto Bar) were incubated at 378C. On 350 day 3 of development, a window was made into the eggshell after puncturing the air chamber, and eggs were sealed with BTK tape and returned to the incubator. On day 9 of development, a ring was placed on the CAM, and on day 10, the U251 cell line (2 × 10 6 cells 355 in 20 mL DMEM medium) was placed inside the ring and the eggs were tapped and returned to the incubator. At day 14 of incubation, the control group received 40 mL of 1% DMSO in DMEM without fetal bovine serum and the treated group received 40 mL of 5 mM 360 CHC. After 72 h, (day 17 of development), the chicken embryos were sacrificed by placing them at 2808C for 10 min. CAMs with tumors were dissected, fixed in 4% paraformaldehyde at room temperature, and included in paraffin. Immunohistochemistry on paraffin sec-365 tions of microtumors was performed for MCTs, as previously described for the human samples. The effect of CHC on cell proliferation was assessed by Ki67 immunohistochemistry using the avidin-biotin-peroxidase method (R.T.U. Vectastin Elite ABC kit, Vector 370 Laboratories). Antigen retrieval was performed in the microwave with 10 mM citrate buffer (pH ¼ 6) for 15 min. Digital Images were taken on days 14 and 17 of development in a stereomicroscope (Olympus S2 × 16), using a digital camera (Olympus DP71). At the se-375 lected time points, the in ovo tumor perimeter was measured using the Cell B software (Olympus). Before paraffin inclusion, tumors were photographed ex ovo for blood vessel count. The number of blood vessels was counted in the area inside the ring placed previously 380 in the CAM, using Image J Software (version 1.41; National Institutes of Health). CHC effect on CAM vascularization was performed at day 14 of development for 72 h. At day 17, the CAM was photographed ex ovo for blood vessel count, as described above.
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Statistical Analysis
Data from human tissue samples were analyzed using SPSS statistical software (version 18.0; SPSS). (Table 1 ). There was a significant in-415 crease in MCT1, MCT4, and CD147 expressions in glioblastomas, compared to nontumoral tissues. In addition, CD147 expression increased significantly from diffuse astrocytomas to glioblastomas, but not MCT1 or MCT4 expressions (Table 1) . Of note, MCT1, MCT4, 420 and CD147 were present only in the cytoplasm in nontumoral brain tissue and diffuse astrocytomas (Table 1 , Fig. 1  Q3 ). On the other hand, MCT1 and CD147 were expressed in the plasma membrane of almost all positive glioblastoma cases, whereas MCT4 was only expressed 425 in 56.3% of the total glioblastomas (Table 1, Fig. 1 Table 2 ). In addition, no correlation between MCT1, MCT4, and CD147 expressions with 435 overall survival was observed using a Kaplan -Meier analysis (P ¼ .101, P ¼ .850, P ¼ .871, respectively; data not shown). Furthermore, both MCT1 and CD147 were expressed in microvessels and capillaries of nonneoplastic brain tissue and diffuse astrocytomas 440 (Fig. 1) .
Expression of MCT1, MCT4, and CD147 in Glioma Cell Lines
All glioma cell lines expressed MCT1 and MCT4 and CD147, however, with distinct levels, as detected by 445 Western blot and immunocytochemistry (Fig. 2) . There was prominent MCT1 expression at the plasma membrane of U251, U373, SNB-19, and GAMG cells. MCT4 was expressed at the plasma membrane in U251, U373, SW1783, and GAMG cell lines, whereas 450 for SW1088 and U87 cells, expression was only present in the cytoplasm. CD147 was expressed at the plasma membrane in almost all cell lines.
In Vitro Effect of CHC on Glioma Cells
To assess the role of MCTs on glioblastoma behavior, 455 we used the classical MCT inhibitorCHC. There is evidence that CHC inhibits MCT1 activity, with no apparent cytotoxicity in vivo. 35 Table S1 ). For subsequent studies, 2 cell lines were chosen on the basis of their opposite response to CHC: U251, one of the most sensitive 470 cells, and SW1088, the least sensitive cell line (see Supplementary material, Table S1 ). CHC decreased the total cell biomass over time in a dose-dependent manner in U251 cells; however, the CHC effect was smaller on SW1088 cells (Fig. 3A) . We assessed the gly-475 colytic rates of both cell lines by measuring the extracellular levels of glucose and lactate over time. As can be seen in Fig. 3B , U251 exhibited higher glycolytic rates than SW1088 cells. Then, to evaluate the effect of CHC on metabolic disturbance, glucose consumption 480 and lactate production were evaluated for 8, 12, and 24 h, using 5 mM and 10 mM CHC for U251 and SW1088 cells. Results for U251 showed a significant decrease in glucose consumption for 12 and 24 h and in lactate production for 12 h for 10 mM CHC and 485 24 h for both 5 mM and 10 mM CHC, compared with untreated cells (Fig. 3C ). For SW1088, only 10 mM . Glioblastoma tissues present a strong expression of MCT1 and CD147, mainly at the plasma membrane, whereas MCT4 reactivity was found in both the cytoplasm and the plasma membrane. Pictures were obtained in the microscope Olympus BX61, at 400× magnification. 
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CHC produced a significant decrease in glucose consumption for 24 h, with no significant effect on lactate production over time (Fig. 3C ).
490
In cell proliferation analysis assessed by BrdU assay, CHC decreased the proliferation of U251 over time for the 2 CHC concentrations used (5 mM and 10 mM), whereas for SW1088, this effect was only seen for 10 mM CHC at 72 h of treatment (Fig. 4A) . To deter-495 mine the effect of CHC on glioma cell death and cell cycle distribution, U251 and SW1088 cells were , and CD147 expressions in glioma cells (400× magnification). MCT1 is mainly expressed at the plasma membrane of U251, U373, SNB-19, and GAMG glioma cell lines, whereas MCT4 is present at both plasma membrane and cytoplasm of the different glioma cells. CD147 is expressed at the plasma membrane of some glioma cells, with different levels.
treated during 72 h with 5 mM and 10 mM CHC, respectively. U251 presented a significant increase in the cell population of subG0 phase and a decrease in the 500 cell population of G0/G1 phase of the cell cycle, compared with the control. However, in SW1088, there was a significant increase in the cell population of S Fig. 3 . Effect of the MCT inhibitor, CHC, on total cell biomass and cellular metabolism. (A) The effect of CHC on total biomass of glioma cells was evaluated over time by the sulphorhodamine B assay. CHC inhibited the viability of U251 cells, but not SW1088, over time, in a dose-dependent manner. (B) Metabolic characterization of U251 and SW1088 cells. U251 cells presented higher levels of glucose consumption and lactate production than SW1088 cells. *P ≤ .05, compared U251 with SW1088 cells. (C) The effect of CHC on cellular metabolism was evaluated by extracellular glucose and lactate measurements. CHC induced a significant decrease in glucose consumption and lactate production on U251, compared with SW1088 cells. Results were normalized to total biomass, at each time point. *P ≤ .05, compared 5 mM CHC with DMSO.
# P ≤ .05, compared 10 mM CHC with DMSO. Results are expressed as the mean + SD of at least 3 independent experiments, each in triplicate.
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phase with a decrease in the cell population of G0/G1 phases, but without effect in the cell population of 505 subG0 phase (see Supplementary material, Fig. S2 ).
Through the Annexin V/PI assay, we observed that CHC induced cell death in U251 cells, but not in Sw1088, by a significant increase in late apoptotic/necrotic cell population (Fig. 4B ). According to these 510 results, CHC induced cell death in U251 cell line, having only an effect on proliferation of SW1088 cells.
Thus, CHC appears to have a cytotoxic effect in U251 cells and a cytostatic effect in SW1088 cells.
The importance of MCT activity on cellular migra-515 tion and invasion capacity was assessed by the woundhealing assay and matrigel invasion assay, respectively. Treatment with CHC decreased U251 cell migration for both concentrations of CHC (5 mM and 10 mM), but not for SW1088 cells (Fig. 4C ). In addition, we ob-520 served that 10 mM of CHC induced a significant decrease in U251 cell invasion (Fig. 4C) .
To evaluate the effect of the combination of CHC and TMZ, we assessed U251 cell total biomass with use of the SRB assay. CHC potentiated the effect of TMZ, 525 decreasing its IC 50 value (Fig. 4D) . The CI was ,1 (Fig. 4D) , confirming the synergistic effect of the combination of CHC with TMZ.
To further confirm CHC inhibition of MCT1 as the mechanism of selective toxicity observed in glioblastoma 530 cells, we performed downregulation of MCT1 with use of siRNA in U251, SNB-19, and GAMG cell lines, which exhibited MCT1 expression at the plasma membrane. Downregulation of MCT1 in all 3 cell lines led to an efficient decrease in MCT1 expression, which 535 was accompanied by decrease of CD147 expression in U251 and SNB-19 cells (Fig. 5A) . No effect on MCT4 expression was observed in all 3 cell lines (Fig. 5A ). Similar to MCT1 activity inhibition, downregulation of MCT1 in glioma cells led to a decrease in cell 540 growth over time, being only significant for GAMG cells for 72 h (Fig. 5B) . Likewise, cell proliferation decreased over time for the 3 cell lines (Fig. 5C ).
Downregulation of MCT1 also induced a significant decrease in lactate production in U251 and SNB-19 545 cells for 12 and 24 h and in GAMG cells for 24 h (Fig. 6A) , supporting the role of MCT1 in the maintenance of glycolytic rates. In addition, it was observed that downregulation of MCT1 induced a significant decrease in the cellular migration of U251, SNB -19, 550 and GAMG cells (Fig. 6B) . Downregulation of MCT1 increased the IC 50 values for CHC, compared with control cells, up to 72 h (Fig. 7A ) in all glioma cells used. Furthermore, treatment of siMCT1 cells with CHC did not alter lactate production (Fig. 7B) .
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In Vivo Effect of CHC on Glioma Cells U251 cell line exhibits higher glycolytic rates, and according to the in vitro results obtained in this study, MCT activity appears to have an important role on cell growth, migration, and invasive capacity of these 560 cells. Thus, we evaluated the potential of CHC in vivo with use of the chicken chorioallantoic membrane (CAM) assay, 37 which allows a 3D tumor formation that is important in context of tumor microenvironment and cellular metabolism. U251 cells were grown in the 565 CAM of chicken embryos for 4 days, and treatment with 5 mM CHC was initiated. As shown in Fig. 8A , we observed a difference in tumor size between the control and treated group and in the number of blood vessels formed around the tumor. CHC induced a signif-570 icant decrease in the perimeter of the tumors of the treated group (3.6 mm), compared with the control group (5.2 mm), after 72 h (Fig. 8B ). This treatment also induced a significant decrease in the number of blood vessels around the tumors in the treated group 575 (45 vessels), compared with the control group (35 vessels) (Fig. 8B ). In addition, CHC decreased the proliferation of tumors, presenting 25% Ki67 positive cells in the control group (n ¼ 5), compared with 5% in the CHC group (n ¼ 5) (Fig. 8C and D) . However, there 580 was no clear difference in MCT1 and MCT4 expressions between the control and CHC group (Fig. 8C) , corroborating the results obtained in vitro (see Supplementary material, Fig. S3 ). Furthermore, CHC did not decrease the number of 585 blood vessels when put alone in the CAM under the same conditions (Supplementary material, Fig. S4 ), demonstrating that CHC effect is mediated by the tumor cells and not directly on the CAM vessels.
Discussion
590
Glioblastomas are very aggressive human neoplasms, presenting high resistance to current therapy. 2 Thus, exploitation of new molecular targets becomes crucial in neuro-oncology. It is well established that solid tumors, including glioblastomas, present hypoxic 595 regions and increased glycolysis. It is described that glycolysis is upregulated .3-fold in glioblastomas that in normal brain, 38 accompanied by an increased ratio of lactate to pyruvate. 39 Thus, upregulation of MCTs likely plays an important role in glioma intracellular ho-600 meostasis and, thus, contributes to its high aggressiveness.
In the present study, we observed that MCT1 and MCT4 were upregulated in glioblastomas, compared with nonneoplastic brain tissues. Compared with 605 diffuse astrocytomas, no significant differences were observed, possibly because of the small number of cases evaluated. Our results are in accordance with the study of Froberg et al., 30 who showed that MCT1 was upregulated in glioblastoma tissues (n ¼ 17), compared with 610 normal brain and low-grade astrocytomas (n ¼ 14).
However, unlike our study, the authors did not describe the cellular localization of MCT1 expression, essential for the role of MCTs in intracellular homeostasis. MCT4 expression has not previously been looked at in 615 brain tumors. MCT4 is increased in glioblastomas, compared with nonneoplastic brain tissue, and in a high number of glioblastomas, MCT4 was present in the cytoplasm (43.7% [31/71]), in opposition to MCT1.
The high expression of MCT4 in the cytoplasm may 620 reflect its role in lactate-pyruvate transportation in other intracellular organelles. 40, 41 Thus, our results suggest that MCT1 would be preferentially involved in lactate efflux, as an adaptation to the glycolytic phenotype in glioblastomas. In addition to being an MCT1 625 and MCT4 chaperone, CD147 is described as a key element in oncogenesis 42 and is upregulated in many human tumors. In the present study, CD147 expression increased with malignancy, with a significant increase from nonneoplastic tissue to diffuse astrocytomas and 630 high-grade gliomas. Our results are in accordance with the study of Sameshima et al., in which it was shown that CD147 was highly expressed in glioblastomas (n ¼ 9) but not in low-grade gliomas (n ¼ 9) or nonneoplastic brain tissue (n ¼ 12). 43 In addition, our results
635
showed an association of both MCT1 and MCT4 with CD147 plasma membrane expression, supporting the role of CD147 as chaperone for both MCT isoforms in gliomas.
We observed that MCT1, MCT4, and CD147 are ex-640 pressed in the glioma cell lines studied, however, with different expression levels and cellular localization and with a pattern similar to glioblastoma tissues. To understand the biological role of MCTs, we performed in vitro and in vivo assays using CHC, a classical MCT inhibitor. 645 Despite the availability of other MCTs inhibitors, such as 4,4 ′ -diisothiocyanostilbene-2,2 ′ -disulphonate (DIDS), 44 quercetin, 45 and lonidamine (LND), 46 CHC is the best described in the literature as having MCTs, namely MCT1, as a primary target, 47 which of impor-650 tance, shows no toxicity in in vivo models. 35, 36 Nevertheless, CHC and all the other compounds may have other targets. It is described that CHC inhibits the chloride-bicarbonate exchanger AE1 with lower affinity. 12 DIDS inhibits AE1 more powerfully than 655 MCTs, 12 and quercetin has various intracellular targets, inhibiting signaling molecules involved in cell survival and proliferation. 48 LND inhibits lactate transportation, 46 ,49 decreasing intracellular pH; 50 however, it is well described that LND primary target is the hexoki-660 nase II (HKII) enzyme activity. 51, 52 We verified that most glioma cell lines were sensitive to CHC, with the exception of SW1088 and SW1783 cells that showed lower sensitivity. The effect of CHC on U251 and SW1088 total cell biomass appears to be 665 related to lactate transportation activity. Accordingly, U251 cells presented higher levels of MCT1 and CD147 at the plasma membrane than did SW1088, and consequently, CHC decreased glucose consumption and lactate production in U251, but not in SW1088 670 cells. A decrease in glucose consumption is an expected result, because the blockage of lactate efflux likely leads to glycolysis arrest. In the sensitive U251 cells, CHC was able to inhibit cell proliferation and induce cell death, having a cytotoxic effect; however, in the 675 less sensitive SW1088 cells, CHC only inhibited cell proliferation but did not induce cell death, having only a cytostatic effect. We verify that MCT location was in agreement with the CHC effect on cell proliferation and/or cell death. Our findings support the dependence 680 of CHC sensitivity on MCT plasma membrane expression. Results obtained by Mathupala et al. showed that inhibition of MCTs by siRNA 26 and CHC 27 reduced cell viability and lactate efflux and promoted cell death in U87-MG cells; however, they did not associate these 685 results with MCT cellular localization. MCT plasma membrane expression is essential for lactate efflux, contributing to the maintenance of the high glycolytic rates and to acidic microenvironment, important features in tumor invasive phenotype. 6 Thus, assessment of 690 plasma membrane expression becomes crucial to explain the effect of CHC. Despite being described as an inhibitor of pyruvate transportation into the mitochondria, 47 recent studies indicate that CHC does not enter the cell, 27, 36 because its inhibitory effect is depen-695 dent on interactions with membrane proteins accessible from the outside of the cell. It is known that CHC can inhibit different MCT isoforms; 11 however, they have different sensitivities. In this context, in addition to MCT1, CHC could also inhibit MCT4 activity; 700 however, the latter should happen at much higher concentrations, because MCT4 has much lower affinity for CHC (K i values are 5-10 times higher than for MCT1; 50 -100 mM). Because we used concentrations of 0.6 -12 mM CHC, it can be assumed that CHC 705 effect is mediated by MCT1 inhibition.
CHC inhibited the migration and invasion capacity of the glycolytic U251 but not the less glycolytic SW1088 cells, suggesting that the glycolytic phenotype and MCT expression profile have an important role in the migration 710 and invasive capacity of glioma cells, putatively through lactate efflux and consequent contribution to acidic microenvironment. Our results are in accordance with the recent published studies, which demonstrate that classical MCT inhibitors and knockdown of MCT1 and MCT4 reduced 715 the migration and invasion capacity of breast, lung, and glioma cells. 36, 53, 54 Although the recent study published by Mathupala et al. 36 reported that CHC decreases the invasive capacity of glioma cells, the authors did not characterize MCT isoform expression and cellular location in 720 glioma cells, which would be essential to show that the effect of CHC is mediated by lactate efflux inhibition through MCTs. Thus, according to the different MCT expression between both cell lines in study, our results suggest that MCT1 may have a crucial role in the highly in-725 vasive capacity of glioma cells, along with lactate 55 in the tumor microenvironment.
Overall, our results suggest that the effect of CHC on lactate transportation activity, namely lactate efflux, and consequently, proliferation, cell death, migration, and 730 invasion activity may be mediated through MCT1 inhibition. It is known that MCTs are expressed in several human organs, 13 and therefore, some adverse effects are expected because of inhibition of lactate transportation activity by CHC. However, Sonveaux et al. 35 and 735 Colen et al. 36 demonstrated that CHC did not show apparent toxicity in the animal models used. Moreover, it was demonstrated that CHC effects in the normal brain tissue are minimal and do not have a significant impact in the neuron-astrocyte lactate shuttle. 36 
740
In addition, we showed that the use of CHC in combination with TMZ potentiated the effect of TMZ on glioma cell growth. These results suggest that CHC, through lactate transportation inhibition and consequent glycolytic flux arrest, makes glioma cells more 745 sensitive to standard therapy. Thus, CHC becomes a promising drug for adjuvant therapy of patients with glioblastomas, sensitizing glioma cells to standard therapy, anticipating little impact on the integrity and viability of normal brain. The effect of CHC as adjuvant in 750 glioma therapy was also demonstrated by Mathupala et al., 27 who reported that U87-MG cells were more sensitive to radiotherapy with CHC pretreatment. Thus, our results for combination of CHC with standard therapy highlighted the importance to target glioma gly-755 colytic metabolism, namely MCT activity; this will decrease lactate concentrations in the tumor microenvironment and, consequently, decrease the migration and invasive capacity of glioblastomas, which is also associated with resistance to standard therapy. TMZ has been 760 described to have a pro-autophagic 56 and late apoptotic effect, 57 contributing also to an anti-angiogenic activity of gliomas when combined with bevacizumab. 58 These studies showed that the effect of TMZ in vivo was higher than in vitro, when the respective IC 50 values 765 were compared. Thus, the in vitro effect of TMZ could be masked by the cell culture conditions, and it might be important to test the relevance of CHC and TMZ combination in vivo. However, our study showed for the first time that CHC potentiates the action of TMZ, 770 with a synergistic effect.
To clarify the role of MCT1 inhibition as the mechanism of CHC action, we downregulated MCT1 in U251, SNB-19, and GAMG glioma cell lines, which exhibited the highest MCT1 plasma membrane expression togeth-775 er with higher sensitivity to CHC. Downregulation of MCT1 led to a decrease in cell growth, proliferation, and migration, likely because of the observed decrease in lactate production. This indicates that MCT1 has an important role in glioma proliferation and progression. 780 Downregulation of MCT1 expression in glioma cells conferred resistance to CHC, as observed by the increased IC 50 values. Furthermore, treatment of siMCT1 cells with CHC did not change lactate production, providing further evidence for the specificity of 785 CHC for MCT1, because MCT4 is still present at the plasma membrane in these cells, although at lower levels than in MCT1. Of interest, the decrease in CD147 expression after MCT1 downregulation that was observed in U251 and SNB-19 cells was not detect-790 ed in GAMG cells. This fact could be explained by the higher MCT4 membrane expression in GAMG cells, which could have allowed the maintenance of CD147 expression. These observations are in agreement with the interdependence of MCT1/4 and CD147 described 795 in the literature. 54 Overall, inhibition of MCT1 expression was similar to inhibition of MCT1 activity, providing evidence for Miranda-Gonç alves et al.: Targeting lactate transport in gliomas 14 NEURO-ONCOLOGY CHC-inhibition of MCT1 as the mechanism of selective toxicity observed in glioblastoma cells. 800 Furthermore, through in vivo studies, we observed a significant decrease in the size of U251 tumors formed in the CAM, validating the antitumoral activity of CHC against glioma cells. This was further confirmed by a decrease in proliferation of glioma cells with 805 CHC treatment. These observations support the in vitro results, where it was reported that CHC decreases cell growth and promotes cell death. Although the CAM assay is not a full in vivo assay, it has been used as a rapid, economic, and reliable approach for drug screen-810 ing, as demonstrated by other groups. 37,59 -61 In addition, we observed that CHC had an inhibitory effect in the CAM angiogenesis, demonstrated by a significant decrease in the vascularization associated with the formed tumors, which we showed was not attributable 815 to direct effect of CHC on chicken endothelial cells. It is described that lactate increases VEGF production, the major angiogenic factor in the microenvironment, 62 and we observed that CHC decreased lactate production in U251 cells. Therefore, we hypothesized that 820 treatment with CHC decreased tumor size and number of blood vessels, likely because of impairment of tumor glycolytic metabolism and decrease in VEGF production mediated by the decrease in microenvironment lactate concentrations.
825
In summary, in the present study, we demonstrated that MCT1 and MCT4, along with their chaperone CD147, are upregulated at the plasma membrane in glioblastomas. In addition, using in vitro and in vivo glioblastoma models, we demonstrated the effectiveness 830 of inhibiting the activity and expression of MCT1, particularly in more glycolytic cells. Of importance, a synergistic effect between CHC and TMZ was observed. Thus, the use of MCT1 inhibitors and probably other metabolic-targeting drugs should be explored as a 835 novel strategy for glioblastoma treatment.
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